Clinical Trial

Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 Diabetes

Enrolling by Invitation Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated March 5, 2026 (before its estimated March 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This clinical trial aims to evaluate and compare the comparative efficacy and safety of Metformin-Empagliflozin-Sitagliptin vs. Metformin-Empagliflozin-Linagliptin in newly diagnosed Type 2 Diabetes Mellitus patients. The study will involve 110 participants, aged 30-55, enrolled at the National Medical Centre, Karachi, Pakistan. The study involves two groups, subjects will receive the following treatments: Group A will receive Tab Metformin 1000mg + Tab Empagliflozin 12.5mg (FDC) + Tab Sitagliptin 50mg, whereas Group B will receive Tab Metformin 1000mg + Tab Empagliflozin 12.5mg + Tab Linagliptin 2.5mg (FDC) per orally, once daily, for 90 days. Safety and efficacy will be assessed through anthropometric measurements and lab investigations at baseline, 6 weeks, and 12 weeks, with weekly monitoring of blood sugar levels. The total duration of the study will be 6 months, with a 3-month individual treatment period.
Trial Details
NCT Number NCT07452913
Lead Sponsor Bahria University
Conditions Type 2 Diabetes Mellitus
Enrollment 110 participants
Start Date 2026-01-01
Primary Completion 2026-03-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-05